Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells-Reference-Cited by-同舟云学术

Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells

Published:2021-01 Issue:6 Volume:10 Page:
ISSN:2050-0068
Container-title:Clinical & Translational Immunology
language:en
Short-container-title:Clin Transl Immunol

Author:

Bame Eris¹,Tang Hao²,Burns Jeremy C²^ORCID,Arefayene Million¹,Michelsen Klaus³,Ma Bin³,Marx Isaac³,Prince Robin³^ORCID,Roach Allie M²^ORCID,Poreci Urjana¹,Donaldson Douglas¹,Cullen Patrick²,Casey Fergal²,Zhu Jing²,Carlile Thomas M²,Sangurdekar Dipen²,Zhang Baohong²,Trapa Patrick³,Santoro Joseph³,Muragan Param³,Pellerin Alex²,Rubino Stephen²,Gianni Davide³,Bajrami Bekim³,Peng Xiaomei⁴,Coppell Alex⁵,Riester Katherine¹,Belachew Shibeshih⁶,Mehta Devangi¹,Palte Mike⁷,Hopkins Brian T³,Scaramozza Matthew⁷,Franchimont Nathalie⁷,Mingueneau Michael²^ORCID

Affiliation:

1. Clinical Sciences Biogen Cambridge MA USA

2. Biogen Research Biogen Cambridge MA USA

3. Biotherapeutics and Medicinal Sciences Biogen Cambridge MA USA

4. Global Safety and Regulatory Sciences Biogen Cambridge MA USA

5. Clinical Operations Biogen Maidenhead UK

6. Personalized Health Research Biogen Baar Switzerland

7. MS Development Unit Biogen Cambridge MA USA

Funder

Biogen

Publisher

Wiley